Figure 2

The high-risk rs3129882 GG genotype is associated with increased baseline expression and inducibility of major histocompatibility complex class II (MHC-II) messenger RNA (mRNA). RNA was isolated from paramagnetically, positively sorted (a) B cells and (b) monocytes. MHC-II mRNA expression was quantified relative to 18S rRNA with RT-PCR.*P<0.05, **P<0.01, ****P<0.0001. B-cell CTRL GG versus CTRL AA HLA-DRA t(35)=2.01, P<0.05; HLA-DRB1 t(34)=2.04, P<0.05; HLA-DQB1 t(33)=3.28, P<0.01. B-cell PD GG versus PD AA HLA-DRB1 t(25)=1.59, P=0.06; HLA-DQB1 t(33)=1.64, P=0.06. Monocytes CTRL GG versus CTRL AA HLA-DRB1 t(32) =1.90, P<0.05; HLA-DQB1 t(35)=2.08, P<0.01; PD GG versus PD AA HLA-DRB1 t(26)=2.24, P<0.05; HLA-DQB1 t(30)=2.28, P<0.05. (c) Fold change in MHC-II expression with or without 100 U/ml interferon-γ stimulation in paramagnetically, positively sorted monocytes was measured by RT-PCR after normalization to 18S rRNA levels. One-tailed t-test was performed as indicated. ****P<0.0001 **P<0.01, *P<0.05. CTRL AA versus GG HLA-DRA t(33)=1.77 P<0.05; HLA-DQA1 t(13)=1.80, P<0.05; PD AA versus PD GG HLA-DRA t(36)=1.76, P<0.01; HLA-DRB1 t(29)=1.65, P<0.01; HLA-DQA1 t(24)=1.82, P<0.01; HLA-DQB1 t(30)=2.53, P<0.0001. PD, Parkinson’s disease.